July 2012, Vol 5, No 4
Emerging Trends in Cancer Care: Health Plans’ and Pharmacy Benefit Managers’ Perspectives on Changing Care Models
Nausea and vomiting are 2 serious and related side effects of cancer chemotherapy. These adverse effects can cause significant negative impacts on patients’ quality of life and on their ability to comply with therapy. Also, nausea and vomiting can result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.1,2 Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.
Selecting Best Therapies for Control of Chemotherapy-Induced Nausea and Vomiting
Quang T. Nguyen, DO, Lindsay Sanders, DO, MPH, Anu P. Michael, MD, Scott R. Anderson, MS IV, Loida D. Nguyen, PharmD, BCPS, Zackary A. Johnson, MS II
Cancer has always been a devastating and deadly disease. Unlike many other illnesses, it does not discriminate among populations, and it spares neither young nor old. As our population ages, and the menu for diagnostic tools and treatments becomes more expansive and sophisticated, cancer has been evolving as an increasingly dominant disease for research and discussion. Only 30 years ago, our ability to differentiate subclasses, subtypes, and even the stage of cancer was significantly more limited than it is today.
Approximately 200 oncologists, payers, employers, managed care executives, pharmacy benefit managers, and other healthcare stakeholders convened in Houston, TX, on March 28-31, 2012, for the Second Annual Conference of the Association for Value-Based Cancer Care (AVBCC).
Results 1 - 5 of 5